AGP Executive Report
Last update: 4 hours agoBiotech Deal: Innate Pharma and Sobi struck a strategic partnership to license lacutamab and enable the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma, a key step toward accelerated approval in Sézary syndrome. Ophthalmology & Access: A Medicare analysis found anti-VEGF drug use varies between fee-for-service and Medicare Advantage plans, with aflibercept leading in FFS and bevacizumab in MA. New Eye Products: Harrow relaunched Byooviz, a ranibizumab biosimilar, and Nicox’s China partner Ocumension filed an NDA for NCX 470 to lower intraocular pressure in open-angle glaucoma. Policy & Safety: Cairo pharmacists urged clearer, legible prescriptions and wider electronic prescribing to cut medication errors. Global Health Workforce: Kyrgyzstan plans to staff medical points and a mobile hospital for the VI World Nomad Games, using 600+ specialists. Health Systems & Medicines: Zimbabwe’s local pharma lobby warned public procurement is too low for domestic manufacturers to scale. Politics & Care: Malaysia’s PM Anwar Ibrahim is undergoing medical tests and procedures and will be observed for two days.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
